View contacts for Immunic Therapeutics to access new leads and connect with decision-makers. Copied Senior Scientist/Scientist II, Formulation Development. You will receive a reply to confirm the receipt of your application. Immunomic Therapeutics' continued investment in Process Development provides value in several ways. 2006 Aug 15;177(4):2265-75. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. Prior to joining ITI, Ms. Harrison worked as a consultant for various biotechnology companies focused on oncology and infectious disease, leading client interactions with global regulatory authorities regarding product approvals and regulatory planning and implementation. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . It is important to note that, while the mechanism of lysosomal targeting appears to focus on enhancing presentation of antigen to CD4+ T cells and producing a Th1 type CD4+ T cell response (an aspect missing in other platforms), the UNITE platform, as a whole, is believed to induce a broad immune response and can result in enhanced CD8+ T cell responses as well. DC Inno - Exclusive: Rockville biotech expanding, 'on the prowl' for San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. SaaS, Android, Cloud Computing, Medical Device). Ms. Harrison earned a Bachelor of Science in Biochemistry from San Diego State University. Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND) application for ITI-1000 from the University of Florida (UF). Our Pipeline | Xilio Therapeutics Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform . Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. What is health insurance like at Immunomic Therapeutics. ITI-1000 is a cell therapy powered by ITIs UNITE platform that is currently being evaluated in a Phase II clinical trial (ATTAC-II) in collaboration with researchers at the University of Florida (Dr. Duane Mitchell) and Duke University (Dr. John Sampson). Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000, a pDNA Vaccine, in Development for the Treatment of Merkel Cell Carcinoma November 08, 2022 08:30 AM Eastern Standard Time
Judith Dull Before She Was Murdered,
Does Alan Tudyk Have A Glass Eye,
How Old Was Mariah Carey In Heartbreaker,
Articles I